Skip to content

Ketamine: all studies

Page 419 of 449: studies 4,181 to 4,190 of 4,483, newest first. Back to the ketamine overview

Research

Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia.

Neurochemistry International May 1, 2019 Hidetsugu Fujigaki, Akihiro Mouri, Yasuko Yamamoto et al.

Phencyclidine (PCP) is a dissociative anesthetic that induces psychotic symptoms and neurocognitive deficits in rodents similar to those observed in schizophrenia patients. PCP administration in healthy human subjects induces schizophrenia-like symptoms such as positive and negative symptoms, and a range of cognitive deficits. It has been reported that PCP, ketamine, and related drugs such as...

DOI: 10.1016/j.neuint.2019.02.001 (opens in new tab) Full text (opens in new tab) Kynurenic acid Kynurenine pathway Phencyclidine Quinolinic acid +1

Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation

Journal of Clinical Investigation April 16, 2019 T. Kato, Santosh Pothula, Rong-Jian Liu et al. 88 citations

Preclinical studies demonstrate that rapid acting antidepressants, including ketamine require stimulation of mTORC1 signaling. This pathway is regulated by neuronal activity, endocrine and metabolic signals, notably the amino acid leucine, which activates mTORC1 signaling via binding to the upstream regulator sestrin. Here, we examined the antidepressant actions of NV-5138, a novel highly...

DOI: 10.1172/jci126859 (opens in new tab) Mtorc1 Antidepressant Pharmacology Cell biology +2

Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation

Science April 12, 2019 R. N. Moda-Sava, Mitchell H. Murdock, Puja K Parekh et al.

Why is ketamine an antidepressant? A better understanding of the mechanisms underlying the action of antidepressants is urgently needed. Moda-Sava et al. explored a possible mode of action for the drug ketamine, which has recently been shown to help patients recover from depression (see the Perspective by Beyeler). Ketamine rescued behavior in mice that was associated with depression-like...

Relationship of critical dynamics, functional connectivity, and states of consciousness in large‐scale human brain networks

Neuroimage March 1, 2019 Heonsoo Lee, Daniel Golkowski, Denis Jordan et al.

ABSTRACT Recent modeling and empirical studies support the hypothesis that large‐scale brain networks function near a critical state. Similar functional connectivity patterns derived from resting state empirical data and brain network models at criticality provide further support. However, despite the strong implication of a relationship, there has been no principled explanation of how...

Evaluation of dextromethorphan with select antidepressant therapy for the treatment of depression in the acute care psychiatric setting.

Mental Health Clinician March 1, 2019 Jill L Nofziger, Chris Paxos, Jessica Emshoff et al.

Dextromethorphan (DXM), an N-methyl-D-aspartate receptor antagonist, may have ketamine-like antidepressant effects. Dextromethorphan is extensively metabolized via cytochrome P450 (CYP) 2D6, and its half-life in extensive metabolizers is 2 to 4 hours. The purpose of this study was to evaluate the effects of DXM in combination with a moderate-to-strong CYP2D6 inhibitor antidepressant on...

Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports.

Consciousness and Cognition March 1, 2019 Charlotte Martial, Héléna Cassol, Vanessa Charland-Verville et al. 98 citations

The real or perceived proximity to death often results in a non-ordinary state of consciousness characterized by phenomenological features such as the perception of leaving the body boundaries, feelings of peace, bliss and timelessness, life review, the sensation of traveling through a tunnel and an irreversible threshold. Near-death experiences (NDEs) are comparable among individuals of...

DOI: 10.1016/j.concog.2019.01.011 (opens in new tab) Full text (opens in new tab) Phenomenology Near-death experience: nde Profound states Dissociatives: ketamine +3

Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study

Journal of Psychoactive Drugs February 9, 2019 Lorenzo Moccia, A. Tofani, Marianna Mazza et al. 10 citations

Novel psychoactive substances (NPSs) have currently become a major public health concern because of relatively easy accessibility to these compounds and difficulty in identifying them with routine laboratory techniques. Here, we report the 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT) case study of a 23-year-old man who developed a...

DOI: 10.1080/02791072.2019.1578444 (opens in new tab) Dorsolateral prefrontal cortex Positron emission tomography Verbal fluency test Working memory +6

Drug overdoses

February 5, 2019 Punit S. Ramrakha, Kevin P. Moore, Amir H. Sam

Abstract This chapter describes drug overdoses, the general approach, and antidotes. It includes information on overdoses of anticonvulsants, antipsychotic drugs, aspirin, benzodiazepines, beta-blockers, calcium channel blockers, carbon monoxide, cyanide, digoxin, ethanol, hypoglycaemic agents, iron, lithium, non-steroidal anti-inflammatory drugs, recreational drugs (stimulants: amphetamines,...

DOI: 10.1093/med/9780198797425.003.0014 (opens in new tab) Drug Pharmacology Tricyclic Hallucinogen

Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects

Nature Communications January 15, 2019 Brendan Hare, R. Shinohara, Rong-Jian Liu et al.

Impaired function in the medial prefrontal cortex (mPFC) contributes to depression, and the therapeutic response produced by novel rapid-acting antidepressants such as ketamine are mediated by mPFC activity. The mPFC contains multiple types of pyramidal cells, but it is unclear whether a particular subtype mediates the rapid antidepressant actions of ketamine. Here we tested two major subtypes,...

Methoxetamine: A foe or friend?

Neurochemistry International 2019 Chrislean Jun Botanas, June Bryan De la Peña, Hee Jin Kim et al.

Methoxetamine (MXE) is an N-methyl-D-aspartate (NMDA) receptor antagonist that is chemically and pharmacologically similar to other dissociative substances, such as ketamine and phencyclidine. There are reports on the misuse of MXE, which sometimes resulted in adverse consequences and death. Studies have also shown that MXE has abuse liability and stimulates dopamine neurotransmission in the...

DOI: 10.1016/j.neuint.2018.10.020 (opens in new tab) Full text (opens in new tab) Abuse liability Antidepressant Intoxication Methoxetamine